You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Moderna未來會如何?
uSMART盈立智投 11-15 22:14

自Moderna(MRNA.US)11月4日公佈三季度財報以來,該股股價一直在穩步下跌。今年迄今爲止,該股上漲了121%,不過在過去一個月裏則下跌了約26%。

財報顯示,Moderna三季度營收49.69億美元,低於市場預期的62.1億美元;該公司該下調了全年業績預期。此外,該公司還面臨着潛在的法律風險:其新冠疫苗的一項關鍵專利可能會帶來財務影響。該公司堅稱擁有全部專利,而美國國立衛生研究院(National Institutes of Health)則認爲該公司的三名科學家爲該專利做出了貢獻。

該股在18位華爾街分析師中的評級爲“中性”,平均目標價爲272.53美元。不同分析師給出的觀點則褒貶不一。

001.png

ASB Capital對Moderna持悲觀看法,認爲日益激烈的競爭將影響該公司盈利能力,該公司正在研發的新冠疫苗已經是其最有價值的東西了。該行警告稱,Moderna股價可能跌至115美元。分析師Jonathan Weber指出,該公司嚴重依賴新冠疫苗,其高增長時代可能已經結束。

不過,分析師Victor Degurnov則更爲樂觀。他表示,Moderna不僅僅有新冠疫苗,而且“可能在mRNA領域擁有最先進的技術”。分析師稱看漲該股,並表示該股現在處於超賣狀態,近期的股價下跌是市場反應過度,“假設該公司2022財年的淨利潤率爲65%,營收爲200億美元,那意味着其淨利潤將爲130億美元。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account